THE FULL BREAKDOWN
Δ8 THC and HHC are both hemp-derived cannabinoid alternatives synthesized from CBD through chemical conversion. Both produce moderate psychoactive effects roughly intermediate between CBD (none) and Δ9 THC (full). The choice between them comes down to subtle differences in stability, drug testing, and legal status.
Δ8 is an isomer of Δ9 — same molecular formula, different double-bond position. The shift reduces CB1 binding affinity, producing about 70% of Δ9’s psychoactive intensity. Subjective experience: clearer-headed, less anxiety-prone, milder euphoria. Δ8 has the longest commercial history of the synthetic hemp cannabinoids — first commercialized around 2019.
HHC is hexahydrocannabinol — Δ9 THC with all double bonds hydrogenated to single bonds. The hydrogenation makes HHC dramatically more shelf-stable than any natural cannabinoid. HHC produces ~80% of Δ9’s effects with similar subjective character. HHC is newer to commercial markets (2022+) and has less established consumer literature.
For drug testing, HHC has a meaningful advantage. Δ8 metabolizes to the same THC-COOH metabolites as Δ9, making it indistinguishable on standard panels. HHC metabolizes to different compounds, some of which aren’t detected by standard tests. The detection rate is lower (not zero) for HHC.
For shelf stability, HHC wins decisively. A bottle of HHC oil stays potent for years at room temperature. Δ8 oxidizes within months similar to Δ9.
For legal status, both are contested. Δ8 has more state-level bans (20+ states). HHC has fewer (15+ states) but is on a similar regulatory trajectory.
For most consumers seeking a moderate high with hemp-derived legality, HHC is the slightly better choice. The shelf stability + drug test profile + slightly stronger effects justify the small premium over Δ8.
